NASDAQ:PRAN - Prana Biotechnology Stock Price, Price Target & More

$1.96 -0.03 (-1.51 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$1.99
Today's Range$1.93 - $1.97
52-Week Range$1.75 - $3.79
Volume2,849 shs
Average Volume31,217 shs
Market Capitalization$17.44 million
P/E Ratio-3.08
Dividend YieldN/A
Beta-0.16

About Prana Biotechnology (NASDAQ:PRAN)

Prana Biotechnology logoPrana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer's: and that is in Phase IIa clinical trials for the treatment of Huntington's diseases. The company is also developing PBT434, which is in preclinical toxicology stage for the treatment for Parkinson's disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company has a research collaboration agreement with Takeda Pharmaceuticals International, Inc. to slow or prevent neurodegeneration of the gastrointestinal system through PBT434, an investigational movement disorders compound. Prana Biotechnology Limited was founded in 1997 and is based in Melbourne, Australia.

Receive PRAN News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRAN
CUSIPN/A
Phone61-3-9349-4906

Debt

Debt-to-Equity RatioN/A
Current Ratio12.11%
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-3.08
Forward P/E Ratio-2.45
P/E GrowthN/A

Sales & Book Value

Annual Sales$100,000.00
Price / Sales174.44
Cash FlowN/A
Price / CashN/A
Book Value$2.01 per share
Price / Book0.98

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees9
Outstanding Shares8,900,000

How to Become a New Pot Stock Millionaire

Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions

What is Prana Biotechnology's stock symbol?

Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN."

What price target have analysts set for PRAN?

1 brokers have issued 12-month price objectives for Prana Biotechnology's shares. Their predictions range from $4.00 to $4.00. On average, they anticipate Prana Biotechnology's stock price to reach $4.00 in the next twelve months. View Analyst Ratings for Prana Biotechnology.

Who are some of Prana Biotechnology's key competitors?

Who are Prana Biotechnology's key executives?

Prana Biotechnology's management team includes the folowing people:
  • Mr. Geoffrey Paul Kempler B.Sc, Grad.Dip.App.Soc.Psych, Co-Founder, Exec. Chairman, CEO & MD (Age 63)
  • Ms. Kathryn Andrews B.Com, CPA, Chief Financial Officer (Age 51)
  • Ms. Dianne M. Angus, Chief Operating Officer (Age 58)
  • Dr. David A. Stamler M.D., Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 57)
  • Prof. Rudolph Emile Tanzi Ph.D., Chief Scientific Advisor and Member of R&D Advisory Board

Has Prana Biotechnology been receiving favorable news coverage?

News coverage about PRAN stock has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Prana Biotechnology earned a news sentiment score of 0.09 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.38 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Prana Biotechnology?

Shares of PRAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prana Biotechnology's stock price today?

One share of PRAN stock can currently be purchased for approximately $1.96.

How big of a company is Prana Biotechnology?

Prana Biotechnology has a market capitalization of $17.44 million and generates $100,000.00 in revenue each year. The biotechnology company earns $-5,680,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. Prana Biotechnology employs 9 workers across the globe.

How can I contact Prana Biotechnology?

Prana Biotechnology's mailing address is LEVEL 2 369 ROYAL PARADE, PARKVILLE C3, 3052. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected]


MarketBeat Community Rating for Prana Biotechnology (PRAN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  189
MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote "Outperform" if you believe PRAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Prana Biotechnology (NASDAQ:PRAN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Prana Biotechnology in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 104.08%. The high price target for PRAN is $4.00 and the low price target for PRAN is $4.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$4.00N/A
Price Target Upside: 104.08% upside26.18% upside26.18% upsideN/A

Prana Biotechnology (NASDAQ:PRAN) Consensus Price Target History

Price Target History for Prana Biotechnology (NASDAQ:PRAN)

Prana Biotechnology (NASDAQ:PRAN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2018B. RileySet Price TargetBuy -> Buy$4.00MediumView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Dividends

Prana Biotechnology (NASDAQ:PRAN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Prana Biotechnology (NASDAQ PRAN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 38.80%
Institutional Ownership Percentage: 2.35%
Insider Trading History for Prana Biotechnology (NASDAQ:PRAN)

Prana Biotechnology (NASDAQ PRAN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Prana Biotechnology (NASDAQ PRAN) News Headlines

Source:
DateHeadline
Reviewing Prana Biotechnology (PRAN) & Vanda Pharmaceuticals (VNDA)Reviewing Prana Biotechnology (PRAN) & Vanda Pharmaceuticals (VNDA)
www.americanbankingnews.com - March 29 at 1:36 PM
CDTX Fails To Impress, RXII On Watch, OTIC Falls On Analyst DowngradeCDTX Fails To Impress, RXII On Watch, OTIC Falls On Analyst Downgrade
www.finanznachrichten.de - March 20 at 9:29 AM
Financial Comparison: Ionis Pharmaceuticals (IONS) versus Prana Biotechnology (PRAN)Financial Comparison: Ionis Pharmaceuticals (IONS) versus Prana Biotechnology (PRAN)
www.americanbankingnews.com - March 8 at 5:10 PM
Prana Biotechnology (PRAN) Upgraded by ValuEngine to "Sell"Prana Biotechnology (PRAN) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - February 4 at 5:02 PM
Head-To-Head Review: Prana Biotechnology (PRAN) versus Yield10 Bioscience (YTEN)Head-To-Head Review: Prana Biotechnology (PRAN) versus Yield10 Bioscience (YTEN)
www.americanbankingnews.com - January 31 at 5:14 PM
Contrasting Nabriva Therapeutics (NBRV) and Prana Biotechnology (PRAN)Contrasting Nabriva Therapeutics (NBRV) and Prana Biotechnology (PRAN)
www.americanbankingnews.com - January 26 at 1:10 AM
Prana Biotechnology (PRAN) PT Set at $4.00 by B. RileyPrana Biotechnology (PRAN) PT Set at $4.00 by B. Riley
www.americanbankingnews.com - January 7 at 6:50 AM
Prana Biotechnology (PRAN) vs. Ironwood Pharmaceuticals (IRWD) Head to Head SurveyPrana Biotechnology (PRAN) vs. Ironwood Pharmaceuticals (IRWD) Head to Head Survey
www.americanbankingnews.com - January 2 at 5:12 PM
Critical Survey: Pluristem Therapeutics (PSTI) and Prana Biotechnology (PRAN)Critical Survey: Pluristem Therapeutics (PSTI) and Prana Biotechnology (PRAN)
www.americanbankingnews.com - December 30 at 7:42 AM
Financial Comparison: Prana Biotechnology (PRAN) & Its RivalsFinancial Comparison: Prana Biotechnology (PRAN) & Its Rivals
www.americanbankingnews.com - December 26 at 11:54 PM
Head-To-Head Analysis: Prana Biotechnology (PRAN) & Its PeersHead-To-Head Analysis: Prana Biotechnology (PRAN) & Its Peers
www.americanbankingnews.com - December 26 at 5:48 AM
Financial Comparison: Prana Biotechnology (PRAN) and Its PeersFinancial Comparison: Prana Biotechnology (PRAN) and Its Peers
www.americanbankingnews.com - December 24 at 5:34 PM
Prana Biotechnology Ltd (PRAN) Upgraded by ValuEngine to SellPrana Biotechnology Ltd (PRAN) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - October 22 at 1:34 PM
Senestech (SNES) and Prana Biotechnology (PRAN) Head to Head ReviewSenestech (SNES) and Prana Biotechnology (PRAN) Head to Head Review
www.americanbankingnews.com - October 15 at 10:22 AM
BRIEF-Prana Biotechnology files for mixed shelf of upto $50 mlnBRIEF-Prana Biotechnology files for mixed shelf of upto $50 mln
www.reuters.com - October 12 at 8:28 AM
Comparing Nektar Therapeutics (NKTR) & Prana Biotechnology (PRAN)Comparing Nektar Therapeutics (NKTR) & Prana Biotechnology (PRAN)
www.americanbankingnews.com - October 11 at 4:32 AM
The List of Failed Alzheimer’s Drug Treatments Keeps GrowingThe List of Failed Alzheimer’s Drug Treatments Keeps Growing
247wallst.com - September 26 at 7:11 PM
Prana Commences Research Collaboration with Takeda for the Treatment of Parkinsons Disease Gastrointestinal NeuropathologyPrana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal Neuropathology
finance.yahoo.com - July 19 at 5:05 AM
Head to Head Analysis: Prana Biotechnology (NASDAQ:PRAN) & Threshold Pharmaceuticals (THLD)Head to Head Analysis: Prana Biotechnology (NASDAQ:PRAN) & Threshold Pharmaceuticals (THLD)
www.americanbankingnews.com - July 12 at 2:08 PM
UPDATE: Prana Biotech (NASDAQ: PRAN) Announces PBT434 Lowers Alpha-Synuclein & Prevents NeurodegenerationUPDATE: Prana Biotech (NASDAQ: PRAN) Announces PBT434 Lowers Alpha-Synuclein & Prevents Neurodegeneration
www.streetinsider.com - July 7 at 8:15 AM
Todays Research Reports on Stocks to Watch: Opexa Therapeutics and Prana BiotechnologyToday's Research Reports on Stocks to Watch: Opexa Therapeutics and Prana Biotechnology
finance.yahoo.com - July 5 at 9:45 AM
Pranas PBT434 Lowers Alpha-Synuclein and Prevents NeurodegenerationPrana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration
finance.yahoo.com - July 5 at 9:45 AM
BUZZ-U.S. STOCKS ON THE MOVE-ConocoPhillips, Cenovus, Lululemon, Prana Biotech, SAIC - NasdaqBUZZ-U.S. STOCKS ON THE MOVE-ConocoPhillips, Cenovus, Lululemon, Prana Biotech, SAIC - Nasdaq
www.nasdaq.com - March 31 at 8:33 AM
Prana Biotechnology Ltd (PRAN)Prana Biotechnology Ltd (PRAN)
seekingalpha.com - March 30 at 7:36 PM
Prana: Expect Success In Massive Binary EventPrana: Expect Success In Massive Binary Event
seekingalpha.com - March 26 at 8:03 AM

SEC Filings

Prana Biotechnology (NASDAQ:PRAN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Prana Biotechnology (NASDAQ:PRAN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Prana Biotechnology (NASDAQ PRAN) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.